(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vice President Dick Cheney’s life followed the arc of the biggest breakthroughs in cardiovascular medicine - 2Arctic sea ice just dropped to an alarming new low
- 3The 15 Most Powerful Forerunners in Business
- 4The pinch at the pump continues on
- 5Vote In favor of Your Favored Pet Consideration Administration
- 10 Activities to Lift Your Consume and Bust Your Stomach
- Compassion and Association: Building Significant Connections
- Most loved Road Food: Which One Prevails upon You?
- What did the gov’t approve for Israel’s 2026 state budget?
- Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- Closets for Your Room: Plan and Utility Features
- Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- These Cities Led Global Jet-Setting In 2025, According To New Data
- Figure out How to Recognize the Right Areas for 5G Pinnacles\
